121 related articles for article (PubMed ID: 37115209)
1. Correction to: Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.
Hoffmann L; Coras R; Kobow K; López-Rivera JA; Lal D; Leu C; Najm I; Nürnberg P; Herms J; Harter PN; Bien CG; Kalbhenn T; Müller M; Pieper T; Hartlieb T; Kudernatsch M; Hamer H; Brandner S; Rössler K; Blümcke I; Jabari S
Acta Neuropathol; 2023 Jun; 145(6):851-855. PubMed ID: 37115209
[No Abstract] [Full Text] [Related]
2. Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.
Hoffmann L; Coras R; Kobow K; López-Rivera JA; Lal D; Leu C; Najm I; Nürnberg P; Herms J; Harter PN; Bien CG; Kalbhenn T; Müller M; Pieper T; Hartlieb T; Kudernatsch M; Hamer H; Brandner S; Rössler K; Blümcke I; Jabari S
Acta Neuropathol; 2023 Jun; 145(6):815-827. PubMed ID: 36973520
[TBL] [Abstract][Full Text] [Related]
3. The genetic landscape of ganglioglioma.
Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C; Nicolae A; Lack J; Chung HJ; Skarshaug S; Pham TA; Navarro W; Abdullaev Z; Aguilera NS; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
Haematologica; 2020 Apr; 105(4):951-960. PubMed ID: 31439678
[TBL] [Abstract][Full Text] [Related]
5. Clinical variability of neurofibromatosis 1: A modifying role of cooccurring PTPN11 variants and atypical brain MRI findings.
D'Amico A; Rosano C; Pannone L; Pinna V; Assunto A; Motta M; Ugga L; Daniele P; Mandile R; Mariniello L; Siano MA; Santoro C; Piluso G; Martinelli S; Strisciuglio P; De Luca A; Tartaglia M; Melis D
Clin Genet; 2021 Nov; 100(5):563-572. PubMed ID: 34346503
[TBL] [Abstract][Full Text] [Related]
6. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Zhao Y; Yu H; Ida CM; Halling KC; Kipp BR; Geiersbach K; Rumilla KM; Gupta S; Lin MT; Zheng G
JAMA Netw Open; 2021 Jan; 4(1):e2035479. PubMed ID: 33507258
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.
Kaburagi T; Yamato G; Shiba N; Yoshida K; Hara Y; Tabuchi K; Shiraishi Y; Ohki K; Sotomatsu M; Arakawa H; Matsuo H; Shimada A; Taki T; Kiyokawa N; Tomizawa D; Horibe K; Miyano S; Taga T; Adachi S; Ogawa S; Hayashi Y
Haematologica; 2022 Mar; 107(3):583-592. PubMed ID: 33730843
[TBL] [Abstract][Full Text] [Related]
8. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
Lee ST; Ki CS; Lee HJ
Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
[TBL] [Abstract][Full Text] [Related]
11. Activating Mutations in
Takada M; Smyth LA; Thaiwong T; Richter M; Corner SM; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31277422
[TBL] [Abstract][Full Text] [Related]
12. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
13. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genetic Analysis of RASopathy in the Era of Next-Generation Sequencing and Definition of a Novel Likely Pathogenic >
Demir S; Yaşar Köstek H; Sanrı A; Yıldırım R; Özgüç Çömlek F; Yalçıntepe S; Deveci M; Atlı Eİ; Atlı E; Eker D; Gürkan H; Tütüncüler Kökenli F
Mol Syndromol; 2022 Feb; 13(2):88-98. PubMed ID: 35418823
[TBL] [Abstract][Full Text] [Related]
15. Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma.
Wang Y; Wang L; Blümcke I; Zhang W; Fu Y; Shan Y; Piao Y; Zhao G
Brain Pathol; 2022 Jan; 32(1):e13011. PubMed ID: 34355449
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.
Papadopoulos G; Papadopoulou A; Kosma K; Papadimitriou A; Papaevangelou V; Kanaka-Gantenbein C; Bountouvi E; Kitsiou-Tzeli S
Eur J Pediatr; 2022 Oct; 181(10):3691-3700. PubMed ID: 35904599
[TBL] [Abstract][Full Text] [Related]
17. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.
Liu YL; Yan Y; Webster C; Shao L; Lensing SY; Ni H; Feng W; Colorado N; Pathak R; Xiang Z; Hauer-Jensen M; Li S; Zhou D; Emanuel PD
Blood; 2016 Apr; 127(15):1912-22. PubMed ID: 26764354
[TBL] [Abstract][Full Text] [Related]
18. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.
Decroocq J; Birsen R; Montersino C; Chaskar P; Mano J; Poulain L; Friedrich C; Alary AS; Guermouche H; Sahal A; Fouquet G; Gotanègre M; Simonetta F; Mouche S; Gestraud P; Lescure A; Del Nery E; Bosc C; Grenier A; Mazed F; Mondesir J; Chapuis N; Ho L; Boughalem A; Lelorc'h M; Gobeaux C; Fontenay M; Recher C; Vey N; Guillé A; Birnbaum D; Hermine O; Radford-Weiss I; Tsantoulis P; Collette Y; Castellano R; Sarry JE; Pasmant E; Bouscary D; Kosmider O; Tamburini J
Leukemia; 2022 May; 36(5):1237-1252. PubMed ID: 35354920
[TBL] [Abstract][Full Text] [Related]
19. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome.
Ekvall S; Sjörs K; Jonzon A; Vihinen M; Annerén G; Bondeson ML
Am J Med Genet A; 2014 Mar; 164A(3):579-87. PubMed ID: 24357598
[TBL] [Abstract][Full Text] [Related]
20. Mutation of
Harigai R; Sato R; Hirose C; Takenouchi T; Kosaki K; Hirose T; Saya H; Arima Y
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
